#United States #Vascular Access #EndoForce™ #Phraxis #Spartanburg, South Carolina

Phraxis Breaks New Ground with EndoForce™ Connector

Phraxis, Inc., a pioneering company in vascular access technology, has announced a significant milestone in the medical field. On August 29, 2025, the very first commercial case utilizing the EndoForce™ Anastomotic Connector was successfully performed at Spartanburg Regional Medical Center, South Carolina. This groundbreaking device marks a monumental step in improving the treatment experience for dialysis patients around the world.

The procedure was overseen by Dr. Ari Kramer, a vascular access surgeon renowned for his role in early clinical advancements involving the EndoForce™. This innovative connector is the first of its kind, specifically designed to standardize dialysis vascular access creation, replacing the traditional hand-sewn surgical sutures that have been prevalent for years.

The EndoForce™ Connector has recently received FDA approval, underscoring its safety and efficacy after extensive trials. This device aims to simplify the process of vascular access, making it more reproducible and efficient compared to conventional methods. According to Dr. Kramer, the introduction of EndoForce™ holds the promise of making graft-to-vein connections more reliable in operating rooms, thus enhancing patient outcomes. “Every decision we make in the OR comes back to the patient,” he stated, emphasizing the device's patient-centered design.

Phraxis, led by its innovative CEO Dr. Alex Yevzlin, views this achievement as the result of over a decade of collaboration with leading surgeons in the field. Dr. Yevzlin expressed pride in bringing such a transformative solution to clinical practice. He stated, “Today represents more than just a first commercial case—it marks the beginning of a new standard in vascular access surgery. Dialysis patients deserve consistent, reliable solutions, and EndoForce™ is designed to deliver on that promise.”

In addition, Geoffrey Beecher, the Chief Commercial Officer of Phraxis, underscored the importance of expanding the availability of EndoForce™. The company plans to collaborate with additional healthcare systems and surgeons, aiming to increase clinical sites where this technology can be employed in the near future.

The South Carolina case represents the official launch of EndoForce™ into the U.S. market, signifying a major advancement not just for Phraxis but for the dialysis community at large. By adopting this innovative approach, the medical profession is taking definitive steps towards standardizing vascular access methods that could significantly improve patient care.

In summary, the EndoForce™ Anastomotic Connector by Phraxis, Inc. is set to revolutionize the field of vascular access for patients undergoing dialysis. The successful first commercial case lays the groundwork for a brighter future in patient care, hinting at a reshaped landscape for dialysis treatments nationwide. For more information on Phraxis and their innovative products, you can visit their website at www.phraxis.com.